The global anti-obesity drugs market was is valued at $1.3bn in 2017

NEW YORK, Dec. 24, 2018 /PRNewswire/ --

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs



Read the full report:



The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 119 tables and 139 figures– all unavailable elsewhere.
The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
- Global Anti-obesity Drugs Market forecast from 2018-2028

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
- Incretion mimetics/GLP-1 agonists
- SNDRIs
- Lipase Inhibitors
- Serotonin receptor agonists
- Sympathomimetic-GABA receptor agonists
- Sympathomimetics

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:
- Long-term Drugs
- Short-term Drugs

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:
- Innovator
- Generic Drugs

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:
- Prescription Drugs
- OTC

This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:
- Saxenda
- Contrave/Mysimba
- Belviq
- Qysmia
- Xenical
- Alli

This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:
- US
- Japan
- EU5: Germany, France, Spain, Italy, UK
- BRIC: Brazil, Russia, China, India
- RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
- Eisai/Arena
- GlaxoSmithKline (GSK)
- Novo Nordisk
- Orexigen/Takeda
- Roche
- Teva
- Vivus

This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
This report gives an overview of pricing and reimbursement in the US and EU.
This report provides a SWOT Analysis of the global anti-obesity drugs market.

Read the full report:

About
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:

SOURCE Reportlinker